KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Payables (2016 - 2025)

Fulgent Genetics (FLGT) has disclosed Payables for 11 consecutive years, with $19.1 million as the latest value for Q4 2025.

  • Quarterly Payables rose 1.89% to $19.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.1 million through Dec 2025, up 1.89% year-over-year, with the annual reading at $19.1 million for FY2025, 1.89% up from the prior year.
  • Payables hit $19.1 million in Q4 2025 for Fulgent Genetics, up from $18.6 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $42.9 million in Q2 2022 to a low of $14.7 million in Q2 2021.
  • Historically, Payables has averaged $22.4 million across 5 years, with a median of $20.0 million in 2022.
  • Biggest five-year swings in Payables: surged 510.86% in 2021 and later tumbled 42.42% in 2023.
  • Year by year, Payables stood at $20.5 million in 2021, then soared by 40.2% to $28.7 million in 2022, then crashed by 42.42% to $16.5 million in 2023, then increased by 13.5% to $18.8 million in 2024, then increased by 1.89% to $19.1 million in 2025.
  • Business Quant data shows Payables for FLGT at $19.1 million in Q4 2025, $18.6 million in Q3 2025, and $19.4 million in Q2 2025.